4.6 Article

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

期刊

BRITISH JOURNAL OF DERMATOLOGY
卷 164, 期 5, 页码 1091-1096

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1365-2133.2011.10213.x

关键词

-

资金

  1. Abbott
  2. Janssen-Cilag
  3. Merck-Serono
  4. MSD
  5. Pfizer

向作者/读者索取更多资源

P>Background Epidemiological data on primary cutaneous lymphomas (PCLs) are rare and have not previously been investigated in Switzerland. Objective To analyse variations in demographics, the pattern of subtypes and staging during the two 10-year intervals, 1990-1999 and 2000-2009. Methods This was a descriptive study of 263 patients with PCL based on a retrospective review and reassessment according to the World Health Organization/European Organization for Research and Treatment of Cancer classification. Results Change was observed in the pattern of cutaneous T-cell lymphoma subtypes: the frequency of Sezary syndrome decreased from 17% to 7% and the frequency of CD30+ lymphoproliferative disorders increased from 7% to 18% (overall P = 0 center dot 04). Staging of PCL showed a higher number of cases of early-stage mycosis fungoides (P = 0 center dot 01). In relation to the international data, the Zurich group had a higher number of patients with Sezary syndrome (11% vs. 3%) and marginal cell lymphoma (14% vs. 5-7%). In addition, comparison of the survival data showed prolonged median overall survival of Zurich patients with Sezary syndrome in the second 10-year interval (6 center dot 5 vs. 2-4 years). Conclusion The increasing frequency of marginal cell lymphoma and CD30+ lymphoproliferative disorders might depend on an increased awareness of these diseases in the medical community, driven by progress in the classification and staging of these disease entities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据